Get this “Fed ticker” before September 16 
Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 GainsWritten by Chris Markoch on September 14, 2026 
Key Points
- Coca-Cola has outperformed the broader market in 2026 while extending its dividend-growth streak to 64 consecutive years.
- Chevron has benefited from strong energy markets, record production, and the integration of Hess while continuing to raise its dividend.
- Merck has rallied sharply as Keytruda remains a powerful earnings driver and its oncology pipeline offers potential growth beyond the drug’s approaching patent cliff.
- Special Report: The Rumors About Elon’s Next Move Are Spreading Fast
Investors who believe that blue-chip stocks mean boring haven’t been paying close attention in 2026. This year, several stocks that have often lagged the S&P 500 are having stellar years, rewarding buy-and-hold investors. To be fair, growth-hungry investors often overlook blue-chip stocks for practical reasons. These are older companies at a mature stage in their business cycle with solid balance sheets that provide predictable gains for investors. However, predictability can also limit the kind of upside growth investors typically chase. Why has the script flipped for several blue-chip stocks in 2026? Some of it is sector rotation as investors look for gains outside of the artificial intelligence (AI) trade. Energy and biotechnology have been among the sectors investors have looked at. But even some consumer-facing stocks are performing well. The stock price return is only one part of the story. Each of these stocks offers an attractive and growing dividend. Together, those dividends and share-price gains can support long-term compounding.
Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold.
Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program.
With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district. See why this overlooked gold explorer could be entering its most important stage
Coca-Cola Stock Delivers Strong Returns and a Growing DividendThe Coca-Cola Co. (NYSE: KO) is a blue-chip stock that’s been made iconic by legendary investor Warren Buffett, who is famously associate with the company is has often spoken about drinking Coca-Cola. Buffett appears to like the product almost as much as he likes the company. Coca-Cola has been a staple in the portfolio of Berkshire-Hathaway (NYSE: BRK.B) for decades. The attributes that attracted Buffett to KO remain in place today. The company has a strong brand; it delivers consistent growth and a growing dividend. Over the last 10 years, KO has delivered a total return of around 177%, including reinvested dividends. In 2026, the stock has also outperformed the S&P 500, with shares up about 25% through early September before dividends. Coca-Cola is a Dividend King, having increased its dividend for 64 consecutive years. Its dividend currently yields 2.41% with a payout of $2.12 per share annually. Coca-Cola has a more diversified portfolio in 2026 than when Berkshire first bought the stock. That’s one reason that the company raised its full-year outlook despite lingering concerns about the health of lower-income consumers and the impact of GLP-1 drugs on the company’s core soft-drink business. Chevron Stock Rides Energy Tailwinds and a Growing DividendMany energy stocks, particularly those in the oil and gas industry, have been outperforming the S&P 500 in 2026. One of the best examples is Chevron Corp. (NYSE: CVX). The integrated oil company has tailwinds from its existing portfolio, which is heavily concentrated in the Permian Basin, along with the benefits of integrating its completed merger with Hess. The company also has an established presence in Venezuela, where it recently expanded its position and outlined plans for additional investment and production growth. Critics may argue that Chevron, like many oil stocks, is enjoying a cyclical tailwind fueled by geopolitical events. But that’s only part of the story. The current infrastructure buildout in the United States will span the rest of this decade and likely beyond. And while renewables may be the future, oil is still very much part of the present. Like Coca-Cola, Chevron is part of the Berkshire Hathaway portfolio. One reason is the company’s growing dividend and commitment to share buybacks. The company is a Dividend Aristocrat, having increased its dividend for 38 consecutive years. In addition to an attractive 3.34% yield, Chevron pays $7.12 per share annually. CVX is up nearly 40% in 2026, more than three times the S&P 500’s gain through early September. Including dividends, the stock’s total return is even stronger.
A little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.25 g/t.
After roughly 21,000 metres of drilling, the company is closing in on its first-ever mineral resource estimate, expected in Q3 or Q4 2026.
That estimate could offer the market its first real look at the scale of this emerging gold system. See what could be next for this US gold explorer
Merck Stock Benefits From Oncology Growth and a Strong PipelineMerck & Co. (NYSE: MRK) rounds out this group of blue-chip stocks that have outperformed the S&P 500 in 2026. The company is best known for its blockbuster oncology drug, Keytruda. It’s hard to minimize the impact of Keytruda on Merck’s financials. The drug, which is approved for several types of cancer across 44 indications and 19 tumor types, accounts for over 55% of the company’s pharmaceutical sales. That's why investors are eyeing the company’s strategy for managing the patent cliff for Keytruda, which begins for some indications in 2028. One reason for optimism is the company’s deep pipeline. That includes the drug it’s developing with Moderna (NASDAQ: MRNA), which delivered positive top-line data in a Phase 3 study in August. This will help position Merck in the emerging field of personalized medicine, particularly in oncology. MRK is up over 40% in 2026, with dividends pushing its total return above that level to over 43%. The company’s dividend yields 2.35% and pays $3.40 per share annually. Merck has increased that dividend for 14 consecutive years. Read this article online › Recommended Stories
Did you find this article useful?  
|
